Probing the protective effects of a conformationally constrained nicotine vaccine

Vaccine

Volumn 30, Issue 47, 2012, Pages 6665-6670

  Moreno, Amira Y ^a   Azar, Marc R ^b   Koob, George F ^b   Janda, Kim D ^a  

^a Departments of Chemistry and Immunology   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Analgesia; Immunotherapy; Nicotine; Self Administration; Vaccination

Indexed keywords

ANTIBODY; NICOTINE; NICOTINE ANTIBODY; NICOTINE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BINDING AFFINITY; DRUG BINDING; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; HAPTENS; HUMANS; IMMUNOGLOBULIN G; MALE; NICOTINE; RATS; RATS, WISTAR; SMOKING CESSATION; TOBACCO USE DISORDER; VACCINES;

EID: 84867469601     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.064     Document Type: Article

References (20)

1. Danaei G., Ding E.L., Mozaffarian D., Taylor B., Rehm J., Murray C.J., et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009, 6(4):e1000058.
2. Quitting smoking among adults-United States, 2001-2010. Morb Mortal Wkly Rep 2011, 60(44):1513-1519.
3. Ino A., Dickerson T.J., Janda K.D. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg Med Chem Lett 2007, 17(15):4115-4121.
4. Hatsukami D.K., Rennard S., Jorenby D., Fiore M., Koopmeiners J., de Vos A., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005, 78(November (5)):456-467.
5. Fahim R.E., Kessler P.D., Fuller S.A., Kalnik M.W. Nicotine vaccines. CNS Neurol Disord Drug Targets 2011, 10(December (8)):905-915.
6. Nabi Biopharmaceuticals. Clinical Trials: NicVAX® (Nicotine Conjugate Vaccine) 2012; Available from: [cited 03.09.12]. http://www.nabi.com/pipeline/clinicaltrials.php.
7. Elmore D.E., Dougherty D.A. A computational study of nicotine conformations in the gas phase and in water. J Org Chem 2000, 65(February (3)):742-747.
8. Meijler M.M., Matsushita M., Altobell L.J., Wirsching P., Janda K.D. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 2003, 125(June (24)):7164-7165.
9. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000, 22(10):809-819.
10. Isomura S., Wirsching P., Janda K.D. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 2001, 66:4115-4121.
11. Moreno A.Y., Azar M.R., Warren N.A., Dickerson T.J., Koob G.F., Janda K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm 2010, 7(April (2)):431-441.
12. Muller R. Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods Enzymol 1983, 92:589-601.
13. Sahley T.L., Berntson G.G. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacology 1979, 65(November (3)):279-283.
14. Aceto M.D., Awaya H., Martin B.R., May E.L. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. Brit J Pharmacol 1983, 79(August (4)):869-876.
15. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008, 8(November (11)):1589-1594.
16. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PloS One 2008, 3(6):e2547.
17. Byrnes-Blake K.A., Laurenzana E.M., Landes R.D., Gentry W.B., Owens S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005, 521(October (1-3)):86-94.
18. Pravetoni M., Keyler D.E., Pidaparthi R.R., Carroll F.I., Runyon S.P., Murtaugh M.P., et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 2012, 83(February (4)):543-550.
19. Moreno A.Y., Mayorov A.V., Janda K.D. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011, 133(May (17)):6587-6595.
20. Carroll F.I., Blough B.E., Pidaparthi R.R., Abraham P., Gong P.K., Deng L., et al. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 2011, 54(July (14)):5221-5228.